Arthur Tzianabos
Director; Director, Interim Executive Chair · 3 filings · Latest: Jun 12, 2026
Q32 Bio Inc.
Stoke Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
STOK | Arthur Tzianabos | Director, Interim Executive Chair | Mar 10, 2026 | Sale | $40.00 | 4,355 | $174.2K | 31,339 | |
STOK | Arthur Tzianabos | Director, Interim Executive Chair | Mar 10, 2026 | Option Exercise | $8.33 | 3,955 | $32.9K | 35,694 | |
STOK | ARTHUR TZIANABOS | — | Mar 10, 2026 | Proposed Sale | $38.31 | 90,508 | $3.5M | — |